Cavendish backs CelLBxHealth turnaround with buy rating, 4p target
CelLBxHealth guides for 50% revenue growth as partnership pipeline swells
CelLBxHealth strikes US clinical collaboration with AdventHealth cancer studies
Enbridge reports record 2025 earnings, reaffirms 2026 guidance
CelLBxHealth shares rise 3% as company continues to focus on cost base
CelLBxHealth drops FDA device listing to cut costs and refocus on revenue growth
CelLBxHealth drops FDA device listing to cut costs and refocus on revenue growth
Nasdaq, Dow Jones little changed as TSMC settles tech jitters
CelLBxHealth backed for rebound by broker
CelLBxHealth enters 2026 with strong pipeline
CelLBxHealth enters 2026 with strong pipeline
Gold prices will keep rising on macroeconomics and geopolitical risk - UBS
Moderna expects 2025 revenue of $1.9B, above guidance
CelLBxHealth Health confirms boardroom appointments
CelLBxHealth Health confirms boardroom appointments
Nasdaq leads market rebound as MongoDB, Credo boost sentiment
CellbxHealth raises just shy of £1m in retail offer
CellbxHealth raises just shy of £1m in retail offer
CelLBxHealth plc (ANPCY) Discusses New Strategy and Business Plan Focused on Commercialization and Liquid Biopsy Innovation Transcript
Apple slashes sales jobs amid strategic restructuring
FTSE 100 Live: London stocks perk up, as banks avoid tax raid
CelLBxHealth plans £6.8 million fundraise as it pushes for commercial reboot
CelLBxHealth plans £6.8 million fundraise as it pushes for commercial reboot
Alphabet shares at all-time high following Gemini 3 release
Silver Mines’ Bowdens drilling delivers best silver intercept in project’s history
Walmart to see continued share gains despite slower sales growth in Q3, analysts project
AI’s great power grab continues in spite of bubble fears
AkzoNobel and Axalta announces all-stock merger creating $25B coatings company
CellBxHealth rises on Qiagen tie-up to push Parsortix into more drug-development projects
ANGLE primed for commercialisation, says leading American investment bank
ANGLE falls on £20mln discounted placing
ANGLE hails Innsbruck prostate cancer treatment data
ANGLE pleased with results of independent study of its Parsortix system
ANGLE looks to change the game for cancer detection